<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Teriparatide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06285</strong></td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Teriparatide (recombinant human parathyroid hormone) is a potent anabolic agent used in the treatment of osteoporosis. It is manufactured and marketed by Eli Lilly and Company.</p></td></tr><tr><th>Protein structure</th><td><img alt="No structure small" src="/assets/no_structure_small-e8790a148b09ecc5ad9f5b4926a538e7.png"></td></tr><tr><th>Protein chemical formula</th><td>C<sub>181</sub>H<sub>291</sub>N<sub>55</sub>O<sub>51</sub>S<sub>2</sub></td></tr><tr><th>Protein average weight</th><td>4117.7150</td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;Parathyroid hormone precursor - Homo sapiens (1-34)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB06285/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Forsteo</td><td>Eli Lilly and Company</td></tr><tr><td>Forteo</td><td>Eli Lilly and Company</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/bone-density-conservation-agents">Bone Density Conservation Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>52232-67-4</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.</td></tr><tr><th>Pharmacodynamics</th><td>Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.</td></tr><tr><th>Mechanism of action</th><td>Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.</td></tr><tr><th>Absorption</th><td>Bioavailability is 95% following subcutaneous injection.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>0.12 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p></td></tr><tr><th>Route of elimination</th><td>Peripheral metabolism of PTH is believed to occur by non-specific enzymatic mechanisms in the liver followed by excretion via the kidneys. The 24-hour urine excretion of calcium was reduced by a clinically unimportant amount (15%).</td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><ul>
	<li>62 L/hr [Women]</li>
	<li>94 L/hr [Men]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Effects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Sanofi aventis us llc</li>
<li>Eli lilly and co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.lilly.com">Eli Lilly &amp; Co.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Subcutaneous</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Forteo 750 mcg/3 ml pen</td><td>295.26USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>6977077</td><td>1999-08-19</td><td>2019-08-19</td></tr><tr><td>United States</td><td>6770623</td><td>1998-12-08</td><td>2018-12-08</td></tr><tr><td>Canada</td><td>2314313</td><td>2005-02-08</td><td>2018-12-08</td></tr><tr><td>Canada</td><td>2325371</td><td>2004-08-17</td><td>2019-08-19</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>liquid</td></tr><tr><th>Experimental Properties</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Stroup J, Kane MP, Abu-Baker AM: Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm. 2008 Mar 15;65(6):532-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18319498">Pubmed</a></li>
	<li>Close P, Neuprez A, Reginster JY: Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother. 2006 Aug;7(12):1603-15. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16872263">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA451620" target="_blank">PA451620 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/teriparatide.html" target="_blank">http://www.drugs.com/cdi/teriparatide.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Teriparatide" target="_blank">Teriparatide <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>H05AA02<ul class="atc-drug-tree"><li><a href="/atc/H#H">H &#8212; SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</a></li><li><a href="/atc/H05#H05">H05 &#8212; CALCIUM HOMEOSTASIS</a></li><li><a href="/atc/H05A#H05A">H05A &#8212; PARATHYROID HORMONES AND ANALOGUES</a></li><li><a href="/atc/H05AA#H05AA">H05AA &#8212; Parathyroid hormones and analogues</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB06285.pdf?1265922745">show</a>(24.4 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>